Monitoring and deciphering protein degradation pathways inside cells

泛素连接酶 泛素 药物发现 三元络合物 蛋白质降解 蛋白质水解 小分子 DNA连接酶 化学 细胞生物学 降级(电信) 连接器 药物开发 靶蛋白 生物 生物化学 计算生物学 蛋白酶体 药品 药理学 计算机科学 操作系统 基因 电信
作者
Danette L. Daniels,Kristin M. Riching,Marjeta Urh
出处
期刊:Drug Discovery Today: Technologies [Elsevier BV]
卷期号:31: 61-68 被引量:45
标识
DOI:10.1016/j.ddtec.2018.12.001
摘要

A new series of therapeutic modalities resulting in degradation of target proteins, termed proteolysis targeting chimeras (PROTACs), hold significant therapeutic potential with possible prolonged pharmacodynamics, improved potency, and ability to target proteins previously thought of as “undruggable”. PROTACs are heterobifunctional small molecules consisting of a target binding handle bridged via a chemical linker to an E3 ligase handle which recruit the E3 ligase and ubiquitin machinery to target proteins, resulting in subsequent ubiquitination and degradation of the target. With the generation of small molecule PROTAC compound libraries for drug discovery, it becomes essential to have sensitive screening technologies to rapidly profile activity and have assays which can clearly inform on performance at the various cellular steps required for PROTAC-mediated degradation. For PROTAC compounds, this has been particularly challenging using either biochemical or cellular assay approaches. Biochemical assays are highly informative for the first part of the degradation process, including optimization of compound binding to targets and interrogation of target:PROTAC:E3 ligase ternary complex formation, but struggle with the remaining steps; recruitment of ternary complex into larger active E3 ligase complexes, ubiquitination, and proteasomal degradation. On the other hand, cellular assays are excellent at determining if the PROTAC successfully degrades the target in its relevant setting but struggle as early development PROTAC compounds are often poorly cell-permeable given their high molecular weight. Additionally, if degradation is not observed in a cellular assay, it is difficult to deconvolute the reason why or at which step there was failure. In this review we will highlight the current approaches along with recent advances to overcome the challenges faced for cellular PROTAC screening, which will enable and advance drug discovery of therapeutic degradation compounds.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
aging00完成签到,获得积分20
1秒前
硅负极发布了新的文献求助10
1秒前
恶恶么v完成签到,获得积分10
1秒前
小羽毛发布了新的文献求助10
1秒前
菜鸟队长完成签到,获得积分10
1秒前
一蓑烟雨任平生完成签到,获得积分10
1秒前
1秒前
欧阳懿完成签到,获得积分10
2秒前
Celia完成签到,获得积分10
2秒前
冷静凌雪完成签到,获得积分10
2秒前
3秒前
852应助Yangfan采纳,获得10
3秒前
3秒前
啦啦啦完成签到,获得积分10
4秒前
数学情缘发布了新的文献求助10
4秒前
NexusExplorer应助aging00采纳,获得10
4秒前
Cm666完成签到,获得积分10
4秒前
4秒前
一一完成签到,获得积分10
4秒前
4秒前
玉子发布了新的文献求助10
5秒前
5秒前
沉静的迎荷完成签到 ,获得积分10
5秒前
hhyyrrr完成签到,获得积分20
5秒前
菜心完成签到,获得积分10
5秒前
6秒前
想吃泡粉完成签到,获得积分10
6秒前
zhenzhangfynu完成签到,获得积分10
6秒前
打小就帅完成签到,获得积分10
6秒前
叉叉茶完成签到,获得积分10
7秒前
SSSS完成签到,获得积分10
7秒前
复杂函完成签到,获得积分10
7秒前
一一完成签到 ,获得积分10
7秒前
Saliyan发布了新的文献求助10
7秒前
orixero应助凯蒂采纳,获得10
8秒前
Keira完成签到,获得积分10
8秒前
张张完成签到 ,获得积分10
8秒前
多发文章完成签到,获得积分10
8秒前
零零零零完成签到,获得积分10
9秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Handbook of pharmaceutical excipients, Ninth edition 5000
Aerospace Standards Index - 2026 ASIN2026 2000
Digital Twins of Advanced Materials Processing 2000
晋绥日报合订本24册(影印本1986年)【1940年9月–1949年5月】 1000
Social Cognition: Understanding People and Events 1000
Polymorphism and polytypism in crystals 1000
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 物理 生物化学 化学工程 计算机科学 复合材料 内科学 催化作用 光电子学 物理化学 电极 冶金 遗传学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 6035102
求助须知:如何正确求助?哪些是违规求助? 7749765
关于积分的说明 16209523
捐赠科研通 5181669
什么是DOI,文献DOI怎么找? 2773099
邀请新用户注册赠送积分活动 1756248
关于科研通互助平台的介绍 1641061